Liza Laws, Author at Labiotech.eu

News and Trends 29 Nov 2022

Mycotechnology and IFF join forces in Europe to create better food system

Mycotechnology, a company using mycelia, the roots of mushrooms, and IFF have formed a partnership to co-develop alternative proteins. The two companies have already partnered in the U.S. and the new collaboration in Europe, they say, reflects their shared commitment of bringing a better food system and ‘next-generation’ food and drink products to the European […]

November 29, 2022 - 2 minutesmins - By Liza Laws

News and Trends 29 Nov 2022

BioPharma Dynamics expands to provide more solutions for cell and gene therapy industry

BioPharma Dynamics have expanded their portfolio for the cell and gene therapy market to offer a range of chemically defined T-Cell media, DMSO-free cryopreservation solutions, and recombinant growth factors. Suitable for cell therapy applications at any stage, the portfolio of cell media products include immune cell media, stem cell media, and cell cryopreservation solutions. Supporting applications which […]

November 29, 2022 - 2 minutesmins - By Liza Laws

News and Trends 28 Nov 2022

Aptamer opens new facilities to meet growing demand for Optimer technology

Aptamer Group developer of Optimer binders that enable development in the life sciences industry has opened new facilities in the UK’s York Science Park. It says this will enable it to meet the growing demand for Optimer technology. Well-known and respected neuroscience researcher, Baroness Susan Greenfield, opened the new 18,000 square-foot site on November 25. […]

November 28, 2022 - 2 minutesmins - By Liza Laws

News and Trends 28 Nov 2022

Lyvgen and Bristol Myers Squibb commitment to transform cancer care

Lyvgen Biopharma announced yesterday that it has started a phase 2 trial of LVGN7409 plus docetaxel or, in collaboration with Bristol Myers Squibb, nivolumab in patients with advanced/metastatic non-small cell lung cancer (NSCLC). “Lyvgen clinical collaboration with Bristol Myers Squibb underscores our commitment to exploring combination regimens from our portfolio with complementary mechanisms of action […]

November 28, 2022 - 3 minutesmins - By Liza Laws

More News! 28 Nov 2022

Monkeypox stigma and racism set to end by renaming to mpox, WHO reports

The World Health Organisation (WHO) said today (November 28) it will begin using mpox, as a synonym for monkeypox. The organization confirmed that both names will be used simultaneously for a year while monkeypox is phased out. This is because of stigmatizing language and monkeypox racism that was appearing online. Some communities observed and reported […]

November 28, 2022 - 4 minutesmins - By Liza Laws

News and Trends 28 Nov 2022

STORM Therapeutics doses first patient with drug targeting solid tumors

STORM Therapeutics Ltd, announced today that the first patient in a phase 1 study had been dosed with a drug targeting solid tumors. The biotech company works on discovering and developing new small molecule therapies targeting RNA modifying enzymes (RMEs) for oncology and other diseases. The patient was dosed with STC-15, STORM’s clinical candidate. It […]

November 28, 2022 - 2 minutesmins - By Liza Laws

News and Trends 28 Nov 2022

Licensing agreement signed for C4XD between C4X Discovery and AstraZeneca

C4X Discovery Holdings plc has signed an exclusive worldwide licensing agreement with AstraZeneca. It is worth up to $402 million, for its NRF2 Activator program. AstraZeneca will develop and commercialize an oral therapy, C4XD. This is for the treatment of inflammatory and respiratory diseases with a lead focus on chronic obstructive pulmonary disease (COPD). C4X Discovery will receive […]

November 28, 2022 - 3 minutesmins - By Liza Laws

News and Trends 23 Nov 2022

BIA and Exopharm sign joint research agreement to develop integrated technology

Slovenian-based Sartorius BIA Separations (BIA), a bio-chromatography company, and Australia’s Exopharm Ltd., a company working with transformative medicines using exosomes, or extracellular vesicles (EVs), have entered into a formal collaboration. A material transfer agreement has been signed by both companies and an associated collaborative program has been implemented which aims to exploit the synergy of […]

November 23, 2022 - 4 minutesmins - By Liza Laws

News and Trends 23 Nov 2022

Significant therapeutic potential of OSE Immunotherapeutics’ CLEC-1 published

OSE Immunotherapeutics SA has announced the publication of data in the peer-reviewed journal Science Advances on a first-in-class preclinical program with CLEC-1, its novel myeloid immune checkpoint target for cancer immunotherapy. The academic collaboration conducted with Elise Chiffoleau’s team at the Center for Translational Research in Transplantation and Immunology has led to identify CLEC-1 as […]

November 23, 2022 - 3 minutesmins - By Liza Laws

News and Trends 23 Nov 2022

Khondrion’s mitochondrial diseases treatment producing positive results

Clinical-stage pharmaceutical company, Khondrion, discovering and developing therapies targeting primary mitochondrial diseases announced yesterday (November 22) its wholly-owned lead asset sonlicromanol for MELAS spectrum disorder has demonstrated positive treatment results. MELAS spectrum disorder is a rare progressive mitochondrial disease and sonlicromanol will move into a phase 3 registrational study supported by favorable benefit-risk profile. The […]

November 23, 2022 - 5 minutesmins - By Liza Laws

News and Trends 23 Nov 2022

Chiesi marks start of Biotech Center of Excellence for the future of medicine in Parma

An impressive crowd gathered at Chiesi Pharmaceutical Group yesterday (November 21) to mark the much-anticipated start of work at its Biotech Center of Excellence, bringing the future of medicine to Parma. Guests, which included Vice Minister of Business and Made in Italy, Valentino Valentini, joined to celebrate the start of the work on the building, […]

November 23, 2022 - 5 minutesmins - By Liza Laws

News and Trends 23 Nov 2022

First patients dosed with Infex Therapeutics’ RESP-X for chronic respiratory disease

A new anti-virulence therapy, RESP-X, treating Pseudomonas aeruginosa (Pa) infections in non-cystic fibrosis bronchiectasis (NCFB) patients has been given to the first subjects in a trial run by Infex Therapeutics. Infex Therapeutics is an anti-infectives company and announced the first subjects were dosed in the phase 1 study in healthy volunteers evaluating the company’s lead […]

November 23, 2022 - 3 minutesmins - By Liza Laws

Resources

Categories

Swiss biotech going strong in 2024: 18 companies to put on your radar

The ABC of biotech startup funding

Approaches

Therapeutic areas

Bridge RNA: A new gene editing technique that could overcome the limitations of CRISPR

Special Olympics: How is biotechnology revolutionizing sports performance worldwide?

R&D

BD

World biotech leaders

Connect with decision-makers and researchers worldwide for collaborative opportunities

Company

Join Us

Subscribe to our newsletter

Advertise with us

Swiss biotech going strong in 2024: 18 companies to put on your radar

The ABC of biotech startup funding

Bridge RNA: A new gene editing technique that could overcome the limitations of CRISPR

Special Olympics: How is biotechnology revolutionizing sports performance worldwide?

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

Liza Laws

Articles by Liza Laws

Mycotechnology and IFF join forces in Europe to create better food system

BioPharma Dynamics expands to provide more solutions for cell and gene therapy industry

Aptamer opens new facilities to meet growing demand for Optimer technology

Lyvgen and Bristol Myers Squibb commitment to transform cancer care

Monkeypox stigma and racism set to end by renaming to mpox, WHO reports

STORM Therapeutics doses first patient with drug targeting solid tumors

Licensing agreement signed for C4XD between C4X Discovery and AstraZeneca

BIA and Exopharm sign joint research agreement to develop integrated technology

Significant therapeutic potential of OSE Immunotherapeutics’ CLEC-1 published

Khondrion’s mitochondrial diseases treatment producing positive results

Chiesi marks start of Biotech Center of Excellence for the future of medicine in Parma

First patients dosed with Infex Therapeutics’ RESP-X for chronic respiratory disease

Subscribe to our newsletter to get the latest biotech news!